We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+11.1%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$440M
AUM Growth
+$9.07M
Cap. Flow
-$6.96M
Cap. Flow %
-1.58%
Top 10 Hldgs %
52.42%
Holding
87
New
10
Increased
20
Reduced
29
Closed
4
Avg Time Held
12 quarters
Top 10 Avg Time Held
8.6 quarters
Top 20 Avg Time Held
11.3 quarters

Top Buys

Rank Stock Value
1
CMPS icon
Compass Pathways
CMPS
+$10.8M
2
NKTR icon
Nektar Therapeutics
NKTR
+$5.13M
3
LRMR icon
Larimar Therapeutics
LRMR
+$4.36M
4
BCAX icon
Bicara Therapeutics
BCAX
+$2.76M
5
FULC icon
Fulcrum Therapeutics
FULC
+$1.9M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$9.76M
2
AXGN icon
Axogen
AXGN
+$7.38M
3
ATXS icon
Astria Therapeutics
ATXS
+$3.99M
4
RVMD icon
Revolution Medicines
RVMD
+$2.41M
5
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$2.25M

Sector Composition

Rank Sector Weight
1 Healthcare 87.01%
2 Miscellaneous 12.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RVMD icon
1
Revolution Medicines
RVMD
$40.4B
$56.5M 12.85%
580,678
-23,836
-4% -$2.41M
2020 Q4
21 quarters
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$40.7M 9.25%
318,505
-18,000
-5% -$2.25M
2022 Q1
16 quarters
STXS icon
3
Stereotaxis
STXS
$106M
$25.2M 5.73%
13,680,554
– –
2013 Q2
51 quarters
DAWN icon
4
DELISTED
Day One Biopharmaceuticals
DAWN
$21M 4.77%
978,463
-20,700
-2% -$292K
2023 Q2
11 quarters
ATRC icon
5
AtriCure
ATRC
$2.89B
$17M 3.88%
597,431
– –
2013 Q2
51 quarters
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.31B
$15.9M 3.61%
476,740
-30,000
-6% -$1.01M
2020 Q3
22 quarters
XENE icon
7
Xenon Pharmaceuticals
XENE
$3.33B
$14.6M 3.32%
250,772
-37,167
-13% -$1.71M
2015 Q3
42 quarters
CYTK icon
8
Cytokinetics
CYTK
$8.57B
$14.3M 3.26%
217,497
-153,500
-41% -$9.76M
2021 Q3
18 quarters
CMPS icon
9
Compass Pathways
CMPS
$1.54B
$13.4M 3.04%
2,418,882
+1,607,836
+198% +$10.8M
2023 Q3
10 quarters
NKTR icon
10
Nektar Therapeutics
NKTR
$1.29B
$11.9M 2.7%
165,178
+90,180
+120% +$5.13M
2025 Q2
3 quarters
IBB icon
11
iShares Biotechnology ETF
IBB
$10.2B
$10.5M 2.39%
62,095
-6,000
-9% -$1.03M
2016 Q4
37 quarters
RCUS icon
12
Arcus Biosciences
RCUS
$2.87B
$9.59M 2.18%
443,829
+12,500
+3% +$270K
2020 Q1
24 quarters
NBIX icon
13
Neurocrine Biosciences
NBIX
$13.7B
$9.3M 2.12%
70,615
– –
2016 Q1
40 quarters
LRMR icon
14
Larimar Therapeutics
LRMR
$224M
$9.13M 2.08%
2,029,164
+1,090,000
+116% +$4.36M
2018 Q2
31 quarters
BCAX icon
15
Bicara Therapeutics
BCAX
$1.15B
$8.39M 1.91%
421,733
+160,150
+61% +$2.76M
2024 Q4
5 quarters
AXGN icon
16
Axogen
AXGN
$2.12B
$8.28M 1.88%
249,960
-226,866
-48% -$7.38M
2021 Q4
17 quarters
BHVN icon
17
Biohaven
BHVN
$1.72B
$7.15M 1.63%
845,735
-109,500
-11% -$1.2M
2022 Q3
14 quarters
TNDM icon
18
Tandem Diabetes Care
TNDM
$1.16B
$6.81M 1.55%
355,208
– –
2023 Q2
11 quarters
DNLI icon
19
Denali Therapeutics
DNLI
$2.94B
$6.12M 1.39%
318,500
– –
2025 Q1
4 quarters
IPSC icon
20
Century Therapeutics
IPSC
$250M
$5.5M 1.25%
2,434,353
-359,233
-13% -$755K
2021 Q2
19 quarters
DXCM icon
21
DexCom
DXCM
$32.1B
$5.42M 1.23%
86,279
-2,000
-2% -$139K
2017 Q3
34 quarters
KALV icon
22
DELISTED
KalVista Pharmaceuticals
KALV
$5.38M 1.22%
267,402
-89,400
-25% -$1.44M
2021 Q1
20 quarters
ASND icon
23
Ascendis Pharma A/S
ASND
$14.7B
$5.3M 1.21%
23,177
-5,000
-18% -$1.12M
2021 Q4
17 quarters
MBX icon
24
MBX Biosciences
MBX
$2.36B
$5.24M 1.19%
175,465
+10,200
+6% +$347K
2025 Q3
2 quarters
INGN icon
25
Inogen
INGN
$168M
$5.22M 1.19%
845,179
+18,108
+2% +$112K
2019 Q1
28 quarters
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, DAFNA Capital Management held 87 positions worth $440M, up 2.1% from $431M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2026 filing shows 10 new, 20 increased, 29 reduced and 4 closed positions. Its largest new stake was Fulcrum Therapeutics: 205,000 shares worth $1.57M. The largest sale was Cytokinetics, an estimated $9.76M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 87% a quarter earlier, followed by Miscellaneous.

  • DAFNA Capital Management's largest Q1 2026 buy was Fulcrum Therapeutics: 205,000 shares worth $1.57M.
  • DAFNA Capital Management added most to Compass Pathways in Q1 2026, an estimated $10.8M increase.
  • DAFNA Capital Management's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $9.76M.
  • DAFNA Capital Management fully exited Astria Therapeutics in Q1 2026, selling an estimated $3.99M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $440M portfolio in Q1 2026.
  • DAFNA Capital Management opened 10 new positions and closed 4 in Q1 2026.
  • DAFNA Capital Management's portfolio value rose 2.1% quarter-over-quarter to $440M.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.